| References |
Top |
| REF 1 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| REF 2 |
FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217564
|
| REF 3 |
2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
|
| REF 4 |
ClinicalTrials.gov (NCT04270747) A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea?) in Subjects With Neovascular Age-related Macular Degeneration. U.S.National Institutes of Health.
|
| REF 5 |
ClinicalTrials.gov (NCT01436864) A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD. U.S. National Institutes of Health.
|
| REF 6 |
ClinicalTrials.gov (NCT02589821) Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors. U.S. National Institutes of Health.
|
| REF 7 |
ClinicalTrials.gov (NCT02065349) A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety. U.S. National Institutes of Health.
|
| REF 8 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021605)
|
| REF 9 |
ClinicalTrials.gov (NCT01449591) Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients. U.S. National Institutes of Health.
|
| REF 10 |
ClinicalTrials.gov (NCT03848611) CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).. U.S. National Institutes of Health.
|
| REF 11 |
ClinicalTrials.gov (NCT02348359) X-82 to Treat Age-related Macular Degeneration. U.S. National Institutes of Health.
|
| REF 12 |
ClinicalTrials.gov (NCT00570635) A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib. U.S. National Institutes of Health.
|
| REF 13 |
ClinicalTrials.gov (NCT00090532) A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration. U.S. National Institutes of Health.
|
| REF 14 |
ClinicalTrials.gov (NCT04470726) Safety and Efficacy of AIV001 on Low Risk Basal Cell Carcinoma. U.S. National Institutes of Health.
|
| REF 15 |
ClinicalTrials.gov (NCT03845166) A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors. U.S. National Institutes of Health.
|
| REF 16 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012394)
|
| REF 17 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018392)
|
| REF 18 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013170)
|
| REF 19 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011158)
|
| REF 20 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009540)
|
| REF 21 |
Clinical pipeline report, company report or official report of Amgen
|
| REF 22 |
Effects of intravitreal injection of KH902, a vascular endothelial growth factor receptor decoy, on the retinas of streptozotocin-induced diabetic rats. Diabetes Obes Metab. 2012 Jul;14(7):644-53.
|
| REF 23 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| REF 24 |
CA patent application no. 841416, Method of selecting therapeutic indications.
|
| REF 25 |
Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial. Chin J Cancer Res. 2021 Feb 28;33(1):103-114.
|
| REF 26 |
National Cancer Institute Drug Dictionary (drug id 452042).
|
| REF 27 |
Receptor Tyrosine Kinase Inhibitors AG013764 and AG013711 Reduce Choroidal Neovascularization in Rat Eye. Exp Eye Res. 2007 May; 84(5): 922-933.
|
| REF 28 |
Clinical pipeline report, company report or official report of AiViva BioPharma.
|
| REF 29 |
Clinical pipeline report, company report or official report of Exelixis.
|
| REF 30 |
Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst. 2002 Oct 2;94(19):1484-93.
|
| REF 31 |
WO patent application no. 2009,0582,67, Benzomorpholine derivatives and methods of use.
|
| REF 32 |
Vascular Endothelial Growth Factor Gene Therapy Increases Survival, Promotes Lung Angiogenesis, and Prevents Alveolar Damage in Hyperoxia-Induced Lung Injury. Circulation. 2005; 112: 2477-2486.
|
| REF 33 |
US patent application no. 2010,0278,784, Methods and compositions for treating skin conditions.
|
| REF 34 |
ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res. 2000 Feb 15;60(4):970-5.
|
